卡维地洛联合螺内酯治疗慢性心力衰竭疗效观察

Clinical Effects of Carvedilol Combined with Spironolactone in Patients with Chronic Heart Failure

目的:探讨卡维地洛联合螺内酯治疗慢性心力衰竭的临床疗效及安全性。方法:选取笔者所在医院2012年1月-2014年1月期间收治的慢性心力衰竭患者62例,按照随机数字表法分为两组,观察组在常规心衰治疗基础上加用卡维地洛联合螺内酯治疗,对照组仅常规心衰治疗。对两组患者治疗前后的血压(BP)、心室率(HR)、左室射血分数(LVEF)及氨基末端B型利钠肽(NT-pro BNP)水平的变化情况进行对比分析。结果:经观察治疗12周后,两组患者心室率、收缩压明显降低,NYHA心功能分级、左室射血分数(LVEF)、氨基末端B型利钠肽(NT-pro BNP)均明显改善,治疗后观察组各相关指标较对照组改善更加明显,差异均有统计学意义(P<0.05)。结论:常规治疗基础上应用卡维地洛与螺内酯联合治疗慢性心力衰竭可以明显改善患者临床症状及心功能,提高治愈率。

Objective： To investigate the clinical effects and safety of Carvedilol combined with Spironolactone on chronic heart failure.Method： 62 cases of chronic heart failure patients were randomly divided into observation and control group.The observation group was given Carvedilol and Spironolactone with routine treatment.The control group was only treated with routine treatment.Blood pressure （BP）, heart rate（HR）, and N-terminal B-type natriuretic peptide precursor（NT-proBNP） levels were evaluated and measured before and after treatment.Result： After 12 weeks of therapy, the heart rate and SBP decreased obviously（P〈0.05）.Meanwhile NYHA cardiac function classification, LVEF and NT-proBNP significantly improved（P〈0.05）.Conclusion： Carvedilol and Spironolactone with routine treatment can significantly improve cardiac function and clinical symptoms in patients with chronic heart failure.